• Verastem won FDA Fast Track status for VS-7375 in KRAS G12D-mutated advanced non-small cell lung cancer following prior platinum chemotherapy and anti-PD-(L)1.
• Clinical results were already presented, with early Phase 1/2 data reported in March 2026 showing the drug was generally well tolerated.
• Registration-directed Phase 2 study TARGET-D 202 will test a once-daily oral dose in previously treated advanced NSCLC, including patients with untreated brain metastases.
• Program expansion also includes Phase 2 trials in pancreatic cancer and colorectal cancer, supporting a broader push across KRAS G12D tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260603521165) on June 03, 2026, and is solely responsible for the information contained therein.